课题基金 / 基金详情

HIGH DOSE CARBOPLATIN AND PACLITAXEL WITH G-CSF IN NON-SMALL CELL LUNG CANCER

HIGH DOSE CARBOPLATIN AND PACLITAXEL WITH G-CSF IN NON-SMALL CELL LUNG CANCER
高剂量卡铂和紫杉醇联合 G-CSF 治疗非小细胞肺癌
批准号:
6275168
负责人:
Thomas C. Shea
金额:
$1.58万
依托单位国家:
美国
项目类别:
财政年份:
1997
资助国家:
美国
项目状态:
已结题
起止时间:
1997-12-01 至 1998-11-30

项目摘要

项目成果

Thomas C. Shea的其他基金

相似基金

相关文献

中文摘要
翻译
主要目的是评估2 -21天的反应率 卡铂和紫杉醇大剂量化疗周期 支持的G-CSF和外周血祖细胞, 非小细胞肺癌的治疗 次要目的是: a)评价该药物的血液学和非血液学毒性, 诱导治疗,和B)评价毒性和可行性 对非手术患者给予6600 cGvXRT, 接受了两个周期的大剂量卡铂和紫杉醇治疗
英文摘要
The primary objective is to assess the response rate to two-21-day cycles of high dose chemotherapy with carboplatin and paclitaxel supported G-CSF and peripheral blood progenitor cells in patients with Stage III non-small cell lung cancer. The secondary objectives are: a) to evaluate the hematologic and non-hematologic toxicity of this induction treatment, and b) to evaluate the toxicity and feasibility of administering 6600 cGvXRT to nonsurgical patients who have been treated with two cycles of high-dose carboplatin and paclitaxel.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
CORE--PROTOCOL REVIEW AND MONITORING SYSTEM
FILGRASTIM ALONE OR IN COMBINATION W/ R METHUSCF IN BREAST CANCER
PHARMACODYNAMIC MODELING OF ORAL ETOPOSIDE IN RELAPSED NON HODGKINS
PHARMACODYNAMIC MODELING OF ORAL ETOPOSIDE IN RELAPSED NON HODGKINS
海外基金